BioRem (BRM) Q4 2024 earnings summary

Executive summary

• Achieved record annual revenue of $37.4M, up 49% year-over-year, and record order backlog of $56.1M as of December 31, 2024.

• Net earnings for 2024 rose 36% to $3.0M, with EPS increasing to $0.19 basic and $0.16 fully diluted.

• Business development and new product focus drove tangible results; expansion planned for 2025 in new territories and technologies.

Financial highlights

• Annual gross profit increased 43% to $10.1M; annual EBITDA rose to $4.7M from $3.4M in 2023.

• Q4 revenue was $9.3M, down from $12.2M in Q4 2023 and $14.9M in Q3 2024, reflecting customer scheduling.

• Q4 gross margin dropped to 17.2% from 36.1% in Q4 2023 due to lower revenue and project rework costs.

• Q4 net earnings were $194K, down from $2.4M in Q4 2023.

Outlook and guidance

• Plans to expand into new geographic markets and introduce new technological offerings in 2025.

• Management expects geopolitical and tariff pressures in 2025 but believes the company is well positioned with a strong balance sheet and flexible supply chain.